A detailed history of Shell Asset Management CO transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 10,425 shares of HALO stock, worth $550,440. This represents 0.03% of its overall portfolio holdings.

Number of Shares
10,425
Previous 10,535 1.04%
Holding current value
$550,440
Previous $552,000 8.15%
% of portfolio
0.03%
Previous 0.03%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$51.3 - $64.42 $5,643 - $7,086
-110 Reduced 1.04%
10,425 $597,000
Q1 2024

Jul 31, 2024

SELL
$33.68 - $41.95 $22,363 - $27,854
-664 Reduced 5.93%
10,535 $552,000
Q1 2024

May 14, 2024

BUY
$33.68 - $41.95 $87,938 - $109,531
2,611 Added 30.4%
11,199 $456,000
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $85,565 - $108,112
-2,568 Reduced 23.02%
8,588 $317,000
Q3 2023

Nov 08, 2023

SELL
$36.46 - $44.03 $7,073 - $8,541
-194 Reduced 1.71%
11,156 $426,000
Q2 2023

Jul 28, 2023

BUY
$30.28 - $38.74 $71,672 - $91,697
2,367 Added 26.35%
11,350 $409,000
Q1 2023

May 15, 2023

SELL
$32.86 - $55.7 $1,018 - $1,726
-31 Reduced 0.34%
8,983 $343,000
Q4 2022

Feb 07, 2023

SELL
$40.06 - $59.44 $72,428 - $107,467
-1,808 Reduced 16.71%
9,014 $513,000
Q3 2022

Nov 14, 2022

SELL
$38.53 - $51.78 $24,582 - $33,035
-638 Reduced 5.57%
10,822 $428,000
Q2 2022

Aug 09, 2022

BUY
$37.35 - $48.3 $127,811 - $165,282
3,422 Added 42.57%
11,460 $504,000
Q1 2022

May 04, 2022

SELL
$31.97 - $41.06 $37,980 - $48,779
-1,188 Reduced 12.88%
8,038 $321,000
Q4 2021

Feb 09, 2022

BUY
$31.82 - $40.75 $1,400 - $1,793
44 Added 0.48%
9,226 $371,000
Q3 2021

Nov 04, 2021

SELL
$38.47 - $46.42 $15,003 - $18,103
-390 Reduced 4.07%
9,182 $374,000
Q2 2021

Aug 12, 2021

BUY
$38.84 - $51.31 $138,503 - $182,971
3,566 Added 59.37%
9,572 $435,000
Q1 2021

May 10, 2021

SELL
$39.51 - $51.45 $282,101 - $367,353
-7,140 Reduced 54.31%
6,006 $250,000
Q2 2020

Aug 10, 2020

SELL
$16.25 - $26.81 $2,356 - $3,887
-145 Reduced 1.09%
13,146 $352,000
Q1 2020

May 11, 2020

SELL
$13.9 - $21.83 $2,807 - $4,409
-202 Reduced 1.5%
13,291 $239,000
Q4 2019

Feb 13, 2020

SELL
$14.93 - $19.53 $4,404 - $5,761
-295 Reduced 2.14%
13,493 $239,000
Q3 2019

Nov 12, 2019

SELL
$15.2 - $17.69 $1,793 - $2,087
-118 Reduced 0.85%
13,788 $214,000
Q2 2019

Aug 12, 2019

SELL
$14.75 - $17.26 $4,690 - $5,488
-318 Reduced 2.24%
13,906 $239,000
Q1 2019

May 09, 2019

BUY
$13.94 - $17.58 $198,282 - $250,057
14,224 New
14,224 $229,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.